These innate immune parameters (i.e., cytokines, LGLs/CD8+FAS+ cells) that are present during the first week of infection are key to defining differences in infection outcomes and could be used in therapeutic interventions to reduce disease severity in susceptible populations. This evidence concerns the gene CD8A and infection.